Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 19/20 | 0.80 |
| ▸ | EDNRB | P24530 | 6/20 | 0.75 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.75 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | DHPS | P49366 | 1/20 | 0.75 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.75 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13281278 | 0.89 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7945356 | 0.89 | EDNRA (0.61) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL8321906 | 0.88 | EDNRA (0.88) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL16900667 | 0.88 | EDNRA (0.88) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Water SCHEMBL1009968 | 0.88 | EDNRA (0.98) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL12238205 | 0.88 | EDNRA (0.81) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL1723227 | 0.88 | EDNRA (0.73) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL1258816 | 0.86 | EDNRA (0.84) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL3981779 | 0.86 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL13068510 | 0.86 | EDNRA (0.84) | EDNRAEDNRBABCC3ABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011117143-A1 | PROCESS FOR THE PREPARATION OF BOSENTAN | LABORATORIOS LESVI, S.L. (ES) | 2011-09-29 | — | — | WO | disclosed |
| EP-2368884-A1 | Process for the preparation of bosentan | Laboratorios Lesvi, S.L. (ES) | 2011-09-28 | — | — | EP | disclosed |
| WO-2011021216-A2 | IMPROVED PROCESS FOR THE PREPARATION OF 4-(1,1-DIMETHYLETHYL)-N-[6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)[2,2'-BIPYRIMIDIN]-4-YL]BENZENESULFONAMIDE | MSN LABORATORIES LIMITED (IN) | 2011-02-24 | — | — | WO | disclosed |
| WO-2010015623-A1 | PROCESS FOR THE PREPARATION OF ENDOTHELIN RECEPTOR ANTAGONISTS | FARMAPROJECTS, S. A. (ES) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010012637-A1 | PROCESS FOR THE PREPARATION OF BOSENTAN | INKE, S.A. (ES) | 2010-02-04 | — | — | WO | disclosed |
| US-20090258075-A1 | Respiratory Drug Condensation Aerosols and Methods of Making and Using Them | ALEXZA PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2009095933-A2 | IMPROVED AND NOVEL PROCESS FOR THE PREPARATION OF BOSENTAN | MSN LABORATORIES LIMITED (IN) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258075-A1 | Respiratory Drug Condensation Aerosols and Methods of Making and Using Them | LTC4S, PTGER1, PTGES | EDNRA 302/4885EDNRB 239/4885ABCC3 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.